The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
Douglas Buckner Johnson
No relevant relationships to disclose
Christine Marie Lovly
No relevant relationships to disclose
Marisa Flavin
No relevant relationships to disclose
Gregory Dan Ayers
No relevant relationships to disclose
Zhiguo Zhao
No relevant relationships to disclose
Wade Thomas Iams
No relevant relationships to disclose
Anthony John Iafrate
No relevant relationships to disclose
Elizabeth Gates Berry
No relevant relationships to disclose
Charles R Terry
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose
Richard D. Carvajal
Research Funding - Bristol-Myers Squibb
Jeffrey Alan Sosman
No relevant relationships to disclose